Volume 14, Number 8—August 2008
Research
Genetic and Serologic Properties of Zika Virus Associated with an Epidemic, Yap State, Micronesia, 2007
Robert S. Lanciotti*
, Olga L. Kosoy*, Janeen J. Laven*, Jason O. Velez*, Amy J. Lambert*, Alison J. Johnson*, Stephanie M. Stanfield*, and Mark R. Duffy*
, Olga L. Kosoy*, Janeen J. Laven*, Jason O. Velez*, Amy J. Lambert*, Alison J. Johnson*, Stephanie M. Stanfield*, and Mark R. Duffy*
Table 2
Neutralization testing with heterologous flaviviruses of patients infected with ZIKV, Yap State, Micronesia, 2007*
| Patient | Days after onset | PRNT90 titer | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZIKV | DENV1 | DENV2 | DENV3 | DENV4 | JEV | YFV | WNV | SLEV | MVEV | ||
| Primary flavivirus ZIKV | |||||||||||
| 822a | 5 | 320 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 822b | 10 | 2,560 | 10 | 10 | 10 | 10 | <10 | <10 | <10 | <10 | <10 |
| 822c | 24 | 5,120 | 10 | 10 | 10 | 10 | <10 | <10 | <10 | <10 | <10 |
| 830a | 2 | <10 | <10 | NT‡ | NT | NT | NT | NT | NT | NT | NT |
| 830b | 21 | 2,560 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 849a | 3 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 849b | 18 | 10,240 | <10 | <10 | <10 | <10 | <10 | 20 | <10 | <10 | <10 |
| 862a | 6 | 320 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 | <10 |
| 862b | 20 | 2,560 | 10 | 10 | <10 | <10 | <10 | <10 | <10 | 10 | <10 |
| Secondary flavivirus ZIKV (probable) | |||||||||||
| 817a | 1 | 80 | 80 | 160 | 320 | 160 | <10 | <10 | <10 | 40 | 40 |
| 817b | 19 | 10,240 | 2,560 | 20,480 | 5,120 | 5,120 | 20 | 320 | 160 | 1,280 | 640 |
| 833a | 1 | 160 | 320 | 80 | 40 | 20 | <10 | <10 | <10 | <10 | <10 |
| 833b | 19 | 81,920 | 20,480 | 5,120 | 5,120 | 1,280 | <10 | <10 | 80 | 320 | 320 |
| 844a | 2 | 20 | 1,280 | 640 | 320 | 160 | <10 | <10 | 5 | 20 | 20 |
| 844b | 16 | 10,240 | 40,980 | 10,240 | 5,120 | 1,280 | 5 | <10 | 160 | 640 | 640 |
| 955a | 1 | 40 | 1,280 | 640 | 160 | 320 | <10 | <10 | <10 | 20 | 20 |
| 955b | 14 | 163,840 | 81,920 | 20,480 | 10,240 | 5,120 | 10 | <10 | 640 | 2,560 | 1,280 |
| 968a | 1 | 80 | 320 | 320 | 80 | 40 | <10 | <10 | <10 | 40 | 20 |
| 968b | 3 | 10,240 | 640 | 640 | 160 | 160 | <10 | <10 | 10 | 40 | 20 |
| 839a | 3 | <10 | <10 | 10 | <10 | <10 | <10 | 40 | <10 | <10 | <10 |
| 839b | 20 | 10,240 | 40 | 320 | 80 | 80 | <10 | 640 | 40 | 80 | 80 |
| 847a | 5 | <10 | <10 | <10 | <10 | <10 | <10 | 640 | <10 | <10 | <10 |
| 847b | 8 | 2,560 | 40 | 320 | 160 | 40 | <10 | 1,280 | 80 | 320 | 320 |
*PRNT90 titer, 90% plaque-reduction neutralization test titer; ZIKV, Zika virus; DENV, dengue virus; JEV, Japanese encephalitis virus; YFV, yellow fever virus; WNV, West Nile virus; SLEV, St. Louis encephalitis virus; MVEV, Murray Valley encephalitis virus; NT, not tested (sample depleted).
Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.